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OBJECTIVE—To determine whether deuterium enrichment on
carbons 5 and 3 (C5/C3) in plasma glucose is inﬂuenced by
processes other than gluconeogenesis and, if so, whether these
processes are altered by type 2 diabetes.
RESEARCH DESIGN AND METHODS—In this study, 10
obese diabetic and 10 obese nondiabetic subjects were infused
intravenously with [3,5-
2H2] galactose enriched at a C5-to-C3
ratio of 1.0 as well as the enrichment of deuterium on C5 and C3
of plasma glucose, measured with nuclear magnetic resonance
using the acetaminophen glucuronide method.
RESULTS—The ratio of deuterium enrichment on C5 and C3 of
glucose was 1( P  0.001) in all of the diabetic and nondiabetic
subjects, resulting in a means  SE C5-to-C3 ratio that did not
differ between groups (0.81  0.01 vs. 0.79  0.01, respectively).
CONCLUSIONS—That the C5-to-C3 glucose ratio is 1 indi-
cates that transaldolase exchange, selective retention of deute-
rium at the level of the triose-isomerase reaction, or both occur
in humans. This also indicates that the net effect of these
processes on the C5-to-C3 ratio is the same in people with and
without type 2 diabetes. The possible effects of transaldolase
exchange or selective retention of deuterium (or tritium) at the
level of the triose-isomerase reaction on tracee labeling and
tracer metabolism should be considered when the deuterated
water method is used to measure gluconeogenesis or [3-
3H]
glucose is used to measure glucose turnover in humans.
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T
he deuterated water method is extensively used
to measure gluconeogenesis in humans (1–7).
One premise of this method is that there is
negligible exchange of the lower three carbons
of fructose or sedoheptulose via the transaldolase ex-
change reaction (8). If such exchange does occur, then
glucose can be labeled on the ﬁfth carbon (C5) by simple
exchange with a labeled carbon three (C3) precursor
without net hexose synthesis (9–11). Whereas it is
established that transaldolase exchange can occur in
vitro (9,12), until recently it was not known whether
exchange also occurs in vivo. To address this question,
we infused [3,5-
2H2] glucose enriched at a C5-to-C3 ratio
of 1.07 intravenously in nondiabetic subjects (13). We
observed that the C5-to-C3 deuterium enrichment in
uridine-diphosphoglucose glucose measured using the
acetaminophen glucuronide method was 1 in all six
subjects studied, averaging 0.75 before and 0.67 during a
4-h hyperinsulinemic-euglycemic clamp. Jones et al.
(14) have observed similar effects of transaldolase ac-
tivity on overestimation of the indirect pathway of
glycogen synthesis in ﬁve healthy humans.
These observations are both surprising and disconcert-
ing because they indicate that deuterium on C5 of fruc-
tose-1,6-phosphate was lost during exchange with
unlabeled C3 precursors, presumably via transaldolase
exchange; that deuterium was selectively retained on C3,
presumably due to a kinetic isotope effect at the level of
the triose-isomerase reaction; or that both occurred (Fig.
1). If substantial transaldolase exchange does occur in
humans, then the extent of labeling of C5 glucose with
deuterium following administration of deuterated water
will be determined by both the rate of transaldolase
exchange and the rate of gluconeogenesis (8). Therefore,
the plasma C5 glucose–to–C2 glucose ratio (which is
labeled by both glycogenolysis and gluconeogenesis)
would overestimate the percent of glucose derived from
gluconeogenesis. This also would preclude accurate mea-
surement of gluconeogenesis with any other tracer
method because all assume negligible transaldolase ex-
change (15,16).
Alternatively, selective retention of deuterium on C3
also would reduce the C5-to-C3 ratio. This would be
consistent with in vitro studies that have shown slower
removal of deuterium during the triose-isomerase reaction
due to a kinetic isotope effect (9–11,17). If this were to
also occur in humans, then it would call into question the
ability of [3-
3H] glucose to accurately measure glucose
turnover because retention of tritium due to a kinetic
isotope effect could result in an underestimation of glu-
cose turnover if it caused the hepatic glucose-6-phosphate
pool to be enriched with tracer. If the rate of transaldolase
exchange or the degree of retention of tritium during the
triose-isomerase reaction differs in diabetic and nondia-
betic humans, this would be particularly problematic
because it would confound comparison of gluconeogene-
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glucose turnover measured with [3-
3H] glucose between
groups.
The present study was undertaken to conﬁrm or refute,
in a larger number of subjects, our previous observation
that the C5-to-C3 ratio measured in the plasma glucose
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FIG. 1. The C5-to-C3 ratio of plasma glucose can decrease if unlabeled glyceraldhyde-3-phosphate exchanges with the bottom three carbons of
C5– and C3–labeled fructose-1,6-phosphate via the transaldolase reaction (A), if the deuterium on dihydroxyacetone originating from the third
carbon of frucose-1,6-posphate is retained relative to that originating from the ﬁfth carbon of fructose-1,6-phosphate due to kinetic isotope effect
(i.e., a slower removal) during the triose isomerase reaction (B), or if a combination of both occurs. Hydrogens and oxygens have been omitted
for the sake of clarity. C, carbon; D, deuterium; DHAP, dihydroxyacetone phosphate; fructose-1,6-P, fructose-1,6-phosphate; GAP, glyceraldehyde-
3-phosphate; glucose-1-P, glucose-1-phosphate; glucose-6-P, glucose-6-phosphate; UDP, uridine-diphosphoglucose.
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(13). We also sought to determine whether the degree of
reduction of the C5-to-C3 plasma glucose ratio differs in
diabetic and nondiabetic humans. We addressed these
questions by infusing [3,5-
2H2] galactose to directly label
the plasma-glucose pool in obese nondiabetic and obese
diabetic subjects after an 18-h fast in order to reduce
hepatic glycogen, thereby maximizing plasma glucose en-
richment by minimizing the rate of entry of unlabeled
plasma glucose into the pool. We report that the C5-to-C3
plasma glucose ratio was 1 in all subjects. We also report
that the degree of reduction in the C5-to-C3 ratio did not
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FIG. 1. Continued.
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the net effect of transaldolase exchange or retention of
deuterium on C3 was comparable in the two groups.
RESEARCH DESIGN AND METHODS
After approval of the Mayo Institutional Review Board, 10 diabetic and 10
nondiabetic subjects, matched for age (mean  SE 62  4 vs. 53  5 years,
respectively), BMI (31.2  1.2 vs. 30.3  1.7 kg/m
2), lean body mass (47.4 
4.5 vs. 43.6  2.8 kg), and body fat (44.7  2.5 vs. 46.5  3.3%) provided
written informed consent to participate in the study. Subjects were in good
health, at a stable weight, and did not engage in regular vigorous exercise. The
nondiabetic subjects did not have a history of diabetes in ﬁrst-degree relatives.
Diabetic subjects discontinued oral hypoglycemic medications at least 10 days
before the study. As expected, fasting plasma glucose (152  15 vs. 90  2
mg/dl) and A1C (7.1  0.3 vs. 5.4  0.1%) at the time of study were higher for
diabetic than nondiabetic subjects.
Subjects were instructed to follow a weight maintenance diet consisting of
55% carbohydrates, 30% fat, and 15% protein for a least one week prior to the
study. Subjects were admitted to the Mayo Clinical Research Unit and Center
for Clinical and Translation Science Activities the evening before the study,
ingested a standard 10 kcal/kg dinner at 1800 h, and then remained fasting
thereafter. At 0600 h the following morning, an 18-gauge cannula was inserted
into a forearm vein for tracer infusions. A second 18-gauge cannula was
inserted in a retrograde fashion into a dorsal hand vein of the opposite arm,
and the hand was placed in a heated box (55°C) to enable sampling of
arterialized venous blood. A primed continuous infusion of [6,6-
2H2] glucose
(88 mg prime; 50 mg/h infusion) was started at 0800 h as well as an infusion
of [3,5-
2H2] galactose (Omicron, Biochemicals, IN; C5-to-C3 ratio 1.0) at 200
mg/h until the study end at 1300 h. Arterialized venous blood samples were
collected at 1230, 1240, 1250, and 1300 h for measurements of glucose, insulin,
and C-peptide as well as glucagon concentrations and tracer enrichment.
Analytical techniques. Plasma samples were placed on ice, centrifuged at
4°C, separated, and stored at 20°C until assay. Plasma glucose concentrations
were measured using a glucose oxidase method (Yellow Springs Instrument,
Yellow Springs, OH). Plasma insulin, C-peptide, and glucagon concentrations
were measured using a chemiluminescence assay (Access Assay, Beckman,
Chaska, MN). Body composition was measured using dual-energy X-ray
absorptiometry (Lunar, Madison, WI). Plasma [6,6-
2H2] glucose enrichment
was measured using mass spectrometry (8), and analysis of C3 and C5
deuterium enrichment on plasma glucose was measured using 2H nuclear
magnetic resonance spectroscopy as previously described (18).
Statistical analysis. Data are expressed as means  SE. Values from 1230,
1240, 1250, and 1300 h were averaged for statistical analysis. A paired
Student’s t test was used to determine if the C5-to-C3 ratio was 1, and an
unpaired Student’s t test was used to determine if the C5-to-C3 ratio differed
between the diabetic and nondiabetic subjects. A P  0.05 was considered
statistically signiﬁcant.
RESULTS
Plasma glucose concentrations during the ﬁnal hour of the
study were higher (P  0.001) for diabetic than nondia-
betic subjects (9.13  0.9 vs. 5.1  0.1 mmol/l, respec-
tively). Insulin concentrations were slightly higher (52.5 
10.6 vs. 36.9  5.1 pmol/l; P  0.06) and C-peptide
concentrations signiﬁcantly higher (0.92  0.12 vs. 0.57 
0.01 nmol/l); P  0.05) for diabetic than nondiabetic
subjects. However, glucagon concentrations did not differ
between groups (77.5  6.4 vs. 74.3  7.8 pg/ml) (Fig. 2).
Endogenous glucose production was slightly but not
signiﬁcantly higher for diabetic than nondiabetic subjects
(11.9  0.4 vs. 10.6  0.5 mol  kg
1  min
1, respec-
tively). The C5-to-C3 ratio in plasma glucose was 1( P 
0.001) for all of the diabetic and nondiabetic subjects,
resulting in a mean that did not differ between groups
(0.81  0.01 vs. 0.79  0.01) (Fig. 3).
DISCUSSION
The present study indicates that despite infusing [3,5-
2H2]
galactose enriched at a C5-to-C3 ratio of 1.0, the C5-to-C3
ratio in plasma glucose was 1 in all subjects, with the
extent of the reduction being comparable in those with
and those without type 2 diabetes. To our knowledge,
there are only two possible ways this ratio can be reduced.
As discussed in detail elsewhere (13) and as shown in Fig.
1A, C5 deuterium can be selectively lost during exchange
of the lower three carbons of fructose-1,6-phosphate
(or sedoheptulose) with unlabeled glyceraldhyde-3-phos-
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FIG. 2. Glucose (A), C-peptide (B), insulin (C), and glucagon (D) concentrations observed in the diabetic and nondiabetic subjects.
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be selectively retained due to a kinetic isotope effect (i.e.,
dihydroxyacetone phosphate labeled with deuterium is
converted to glyceraldhyde-3-phosphate more slowly than
unlabeled dihydroxyacetone phosphate) at the level of the
triose-isomerase reaction.
Because we only have measured the C5-to-C3 ratio in
plasma glucose, we cannot distinguish between these two
possibilities. However, the fact that the C5-to-C3 plasma
glucose ratio does not differ in obese diabetic (0.81) and
obese nondiabetic (0.79) subjects fasted for 18 h, is
comparable to that previously observed in nondiabetic
subjects (0.75) fasted for 12 h (13), and does not
appear to change during infusion of insulin (13) is reas-
suring. This implies that error introduced by labeling of
plasma C5 with deuterium via transaldolase exchange
following ingestion of
2H2O or error introduced by use of
[3-
2H] glucose (and presumably [3-
3H] glucose) to measure
glucose turnover is also likely to be the same under these
conditions. However, it remains possible that the rate of
loss of C5 due to an increase or decrease in the rate of
transaldolase exchange in one group could be offset by a
proportionate decrease or increase in retention of C3 at
the level of the triose-isomerase exchange reaction, result-
ing in comparable C5-to-C3 glucose ratios in both groups,
albeit via different mechanisms.
Whereas the present study indicates that the C5-to-C3
ratio is comparably decreased in nondiabetic and well-
controlled type 2 diabetic subjects, we hesitate to recom-
mend applying a correction factor for the calculation of
gluconeogenesis using the deuterated water method be-
cause we do not know the extent to which the decrease in
the C5-to-C3 ratio is due to transaldolase exchange (which
would increase C5 deuterium labeling) or to retention of
deuterium on C3 (which would not inﬂuence C5 deuterium
labeling). In addition, because glucose turnover differed
only minimally in the diabetic and nondiabetic subjects in
the current experiments, we also do not know whether a
correction factor (if necessary) would be the same in the
presence of marked differences in glucose production
(e.g., poorly controlled diabetes). Future studies will need
to address these questions. In the interim, the possible
effects of transaldolase exchange and selective retention
of deuterium (or tritium) at the level of the triose-isomer-
ase reaction should be considered when the deuterated
water method is used to measure gluconeogenesis and
when [3-
3H] glucose is used to measure glucose turnover
in humans.
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